Maria Lascuna
Community Health · Reedley, CANPI 1366584534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Amgen at 31.5% of the total. Among community health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 362 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- GSK$839
- Lilly USA, LLC$401
- AstraZeneca$335
- Boehringer Ingelheim$283
- Novo Nordisk$268
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,514100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 117 | $1,735 |
| GSK | 76 | $839 |
| Lilly USA, LLC | 27 | $401 |
| AstraZeneca | 13 | $335 |
| Boehringer Ingelheim | 15 | $283 |
| Novo Nordisk | 15 | $268 |
| Ardelyx, Inc. | 17 | $167 |
| Otsuka America Pharmaceutical, Inc. | 8 | $161 |
| AbbVie | 8 | $149 |
| Kowa Pharmaceuticals America, Inc. | 10 | $134 |
| BD | 6 | $125 |
| Regeneron Healthcare Solutions, Inc. | 5 | $111 |
| Dexcom, Inc. | 4 | $78 |
| Pfizer | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $63 |
| Shield Therapeutics Inc | 3 | $58 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Philips North America LLC | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Merck | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Bayer | 2 | $36 |
| Cranial Technologies, Inc | 2 | $34 |
| Lifescan, Inc. | 2 | $25 |
| Nevro Corp. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$257
How this compares
$5,514 in reported general payments places this provider in the 95th percentile of 74 community health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 23 | $21,073 |
| OzempicSemaglutide | 13 | $12,325 |
| EliquisApixaban | 13 | $6,762 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,072 |
| Humalog Kwikpen U-100Insulin Lispro | 17 | $2,827 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $2,466 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,166 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,089 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 98 | $1,040 |
| Atorvastatin Calcium | 127 | $911 |
| SynthroidLevothyroxine Sodium | 11 | $823 |
| Omeprazole | 87 | $686 |
| Levothyroxine Sodium | 57 | $642 |
| Gabapentin | 60 | $611 |
| FenofibrateFenofibrate Nanocrystallized | 20 | $589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $283 | $21,07323 claims |
| Novo NordiskOzempic | $268 | $12,32513 claims |
| PfizerEliquis | $67 | $6,76213 claims |
| AbbVieSynthroid | $149 | $82311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 74 community health providers in California.
Other community health in Reedley
- Diane de Vos-SchmidtSan Luis Obispo$2K
- Mi ChangLos Angeles$2K
- Karen JenneLos Angeles$2K
- Lanelle LapigSherman Oaks$2K
- Loann PhanSanta Ana$1K
- Emily NjorogeMerced$1K
- Jasmine RuizEast Palo Alto$808
- Montserrat NoboaSan Diego$789
- Carrie GerdikSun City$778
- Lily KhoshabaWinton$694
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.